Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)
Clinical trial NCT05837806 · RECRUITING
Trial details
- NCT number
- NCT05837806
- Sponsor
- Tianjin Medical University Second Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-30
- Primary completion
- 2026-12-30
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.